Meeting
2018 ASCO Annual Meeting
Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer.
Authors
Mingyi Zhou
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China
Mingyi Zhou , Liankun Li , Xiaobin Wang , Chunyan Wang , Danbo Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5547)
DOI
10.1200/JCO.2018.36.15_suppl.5547
Abstract #
5547
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer treated with modern chemotherapy (FLOT): Experience in patients in Guatemala.
First Author: Rixci Ramirez
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA in plasma as an early predictor for pathological lymph node involvement and (neo-)adjuvant chemotherapy in patients with colon cancer.
First Author: Louise Raunkilde
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.
First Author: Iori Motoo
Poster
2019 ASCO Annual Meeting
Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study).
First Author: Patrick Robelin